Advertisement

Breast Cancer Research and Treatment

, Volume 141, Issue 2, pp 167–172 | Cite as

Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature

  • Eleonora Teplinsky
  • Derrick Cheung
  • Ilan Weisberg
  • Ramon E. A. Jacobs
  • Martin Wolff
  • James Park
  • Kent Friedman
  • Franco Muggia
  • Komal Jhaveri
Review

Abstract

Hepatitis B reactivation can occur with cytotoxic chemotherapy in patients with hepatitis B and cancer. Reactivation can occur in a patient with chronic hepatitis, an inactive carrier, or one with resolved hepatitis. Clinical presentation may range from subclinical elevation of liver enzymes to fatal fulminant hepatic failure. Mammalian target of rapamycin inhibitors, which include everolimus, are a new generation of targeted agents that are currently approved for many cancers (since March 2009) including advanced hormone receptor positive, human epidermal growth factor receptor 2-negative breast cancer, in conjunction with exemestane (as of July 2012). We are therefore still learning the various adverse events that occur with this new class of agents. Here, we present an unfortunate case of fatal hepatitis B reactivation in a woman with metastatic breast cancer treated with everolimus and exemestane. We have detailed the controversies around hepatitis B screening prior to immunosuppressive therapy. Clinicians and patients should be aware of this rare but fatal complication prior to everolimus use, and a detailed history, screening for hepatitis B and prophylactic antiviral treatment should be considered.

Keywords

Hepatitis B virus Everolimus Breast cancer 

References

  1. 1.
    Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529. doi: 10.1056/NEJMoa1109653 PubMedCrossRefGoogle Scholar
  2. 2.
    Pazdur R (2013) FDA Approval of everolimus. http://www.cancer.gov/cancertopics/druginfo/fda-everolimus. Accessed 15 Aug 2013
  3. 3.
    AFINITOR Package insert. Novartis PharmaGoogle Scholar
  4. 4.
    Sezgin Goksu S, Bilal S, Coskun HS (2013) Hepatitis B reactivation related to everolimus. World J Hepatol 5(1):43–45. doi: 10.4254/wjh.v5.i1.43 PubMedCrossRefGoogle Scholar
  5. 5.
    Mizuno S, Yamagishi Y, Ebinuma H, Nakamoto N, Katahira M, Sasaki A, Sakamoto M, Suzuki H, Kanai T, Hibi T (2013) Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier. Clin J Gastroenterol 6(2):188–192. doi: 10.1007/s12328-013-0371-4 PubMedCrossRefGoogle Scholar
  6. 6.
    Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K, Rad001 in Advanced Neuroendocrine Tumors TTSG (2011) Everolimus for advanced pancreatic neuroendocrine tumors. New Eng J Med 364(6):514–523. doi: 10.1056/NEJMoa1009290 PubMedCrossRefGoogle Scholar
  7. 7.
    Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. New Eng J Med 363(19):1801–1811. doi: 10.1056/NEJMoa1001671 PubMedCrossRefGoogle Scholar
  8. 8.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381(9861):125–132. doi: 10.1016/S0140-6736(12)61134-9 PubMedCrossRefGoogle Scholar
  9. 9.
    Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, Group R-S (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456. doi: 10.1016/S0140-6736(08)61039-9 PubMedCrossRefGoogle Scholar
  10. 10.
    Oketani M, Ido A, Uto H, Tsubouchi H (2012) Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 42(7):627–636. doi: 10.1111/j.1872-034X.2012.00998.x PubMedCrossRefGoogle Scholar
  11. 11.
    Maynard JE (1990) Hepatitis B: global importance and the need for control. Vaccine 8 (Suppl):S18–S20CrossRefGoogle Scholar
  12. 12.
    Lok ASF, McMahon BJ (2009) AASLD Practice guideline update: chronic hepatitis B: update 2009. http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Chronic_Hep_B_Update_2009%208_24_2009.10.1007/s10549-013-2681-0. Accessed 15 Aug 2013
  13. 13.
    Kowdley KVWCC, Welch S, Roberts H, Brosgart CL (2012) Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 56(2):422–433. doi: 10.1002/hep.24804 PubMedCrossRefGoogle Scholar
  14. 14.
    Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ (2003) Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70(4):553–561. doi: 10.1002/jmv.10430 PubMedCrossRefGoogle Scholar
  15. 15.
    Shoushtari AH, Shaw RA (2013) Fulminant hepatitis following chemotherapy treatment for breast cancer. BMJ Case Rep. doi: 10.1136/bcr-2012-007017 PubMedGoogle Scholar
  16. 16.
    Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100(1):182–188PubMedGoogle Scholar
  17. 17.
    Hoofnagle JH (2009) Reactivation of hepatitis B. Hepatology 49(5 Suppl):S156–S165. doi: 10.1002/hep.22945 PubMedCrossRefGoogle Scholar
  18. 18.
    Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Fagiuoli S, Grossi P, Lampertico P, Meliconi R, Mangia A, Puoti M, Raimondo G, Smedile A, Italian Association for the Study of the Liver (2007) Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 39(5):397–408. doi: 10.1016/j.dld.2006.12.017 PubMedCrossRefGoogle Scholar
  19. 19.
    Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, Takeuchi M (2010) Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 116(20):4769–4776. doi: 10.1002/cncr.25253 PubMedCrossRefGoogle Scholar
  20. 20.
    Knoll A, Boehm S, Hahn J, Holler E, Jilg W (2004) Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 33(9):925–929. doi: 10.1038/sj.bmt.1704457 PubMedCrossRefGoogle Scholar
  21. 21.
    Ling WH, Soe PP, Pang AS, Lee SC (2013) Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer 108(10):1931–1935. doi: 10.1038/bjc.2013.225 PubMedCrossRefGoogle Scholar
  22. 22.
    Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, Kondo T, Toyoshima N, Ota S, Kobayashi S, Hige S, Toubai T, Tanaka J, Imamura M, Asaka M (2005) Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 79(5):616–619PubMedCrossRefGoogle Scholar
  23. 23.
    Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ (2004) Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90(7):1306–1311. doi: 10.1038/sj.bjc.6601699 PubMedCrossRefGoogle Scholar
  24. 24.
    Manzano-Alonso ML, Castellano-Tortajada G (2011) Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol 17(12):1531–1537. doi: 10.3748/wjg.v17.i12.1531 PubMedCrossRefGoogle Scholar
  25. 25.
    Teng CF, Wu HC, Tsai HW, Shiah HS, Huang W, Su IJ (2011) Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy. Hepatology 54(4):1199–1207. doi: 10.1002/hep.24529 PubMedCrossRefGoogle Scholar
  26. 26.
    Recommendations for routine testing and follow-up for chronic hepatitis B virus (HBV) infection. Centers for disease control and prevention. http://www.cdc.gov/hepatitis/hbv/PDFs/ChronicHepBTestingFlwUp.pdf. Accessed 15 Aug 2013
  27. 27.
    Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, Zon RT, Wong SL (2010) American society of clinical oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28(19):3199–3202. doi: 10.1200/JCO.2010.30.0673 PubMedCrossRefGoogle Scholar
  28. 28.
    Everolimus (RAD001) in Metastatic transitional cell carcinoma of the urothelium, NCT00805129. http://clinicaltrials.gov/show/NCT00805129. Accessed 15 Aug 2013
  29. 29.
    Study of everolimus added to combined hormonal and radiation therapy for high risk prostate cancer, NCT01642732. http://clinicaltrials.gov/show/NCT01642732. Accessed 15 Aug 2013
  30. 30.
    Everolimus plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced neuroendocrine tumors (GI or Lung Origin) (RADIANT-4), NCT01524783. http://clinicaltrials.gov/show/NCT01524783. Accessed 15 Aug 2013
  31. 31.
    S1207 Hormone therapy with or without everolimus in treating patients with breast cancer, NCT01674140.. http://clinicaltrials.gov/ct2/show/NCT01674140?term=swog+1207&rank=1. Accessed 15 Aug 2013
  32. 32.
    Phase III Study of RAD001 Adjuvant Therapy in poor risk patients with diffuse large B-cell lymphoma (DLBCL) of RAD001 versus matching placebo After patients have achieved complete response with first-line rituximab-chemotherapy (PILLAR2), NCT00790036. http://clinicaltrials.gov/show/NCT00790036. Accessed 15 Aug 2013
  33. 33.
    Daily everolimus in combination with trastuzumab and vinorelbine in HER2/neu positive women with locally advanced or metastatic breast cancer (BOLERO-3), NCT01007942.http://clinicaltrials.gov/show/NCT01007942. Accessed 15 Aug 2013
  34. 34.
    Open-label, phase II, study of everolimus plus letrozole in postmenopausal women with ER+Metastatic breast cancer (Bolero-4), NCT01698918. http://clinicaltrials.gov/show/NCT01698918. Accessed 15 Aug 2013
  35. 35.
    A phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in advance breast cancer. (BOLERO-6), NCT01783444. http://clinicaltrials.gov/show/NCT01783444. Accessed 15 Aug 2013
  36. 36.
    Porta C, Osanto S, Ravaud A, Climent M-A, Vaishampayan U, White DA, Creel P, Dickow B, Fischer P, Gornell SS, Meloni F, Motzer RJ (2011) Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 47(9):1287–1298. doi: 10.1016/j.ejca.2011.02.014 PubMedCrossRefGoogle Scholar
  37. 37.
    European Association for the Study of the Liver (2009) Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50(2):227–242. doi: 10.1016/j.jhep.2008.10.001 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Eleonora Teplinsky
    • 1
  • Derrick Cheung
    • 2
  • Ilan Weisberg
    • 2
  • Ramon E. A. Jacobs
    • 3
  • Martin Wolff
    • 2
  • James Park
    • 2
  • Kent Friedman
    • 4
  • Franco Muggia
    • 1
  • Komal Jhaveri
    • 1
  1. 1.New York University Cancer InstituteNew YorkUSA
  2. 2.Division of Gastroenterology, Department of MedicineNew York University School of MedicineNew YorkUSA
  3. 3.Department of MedicineNew York University Langone Medical CenterNew YorkUSA
  4. 4.Division of RadiologyNew York University Langone Medical CenterNew YorkUSA

Personalised recommendations